Spironolactone in Patients With Single Ventricle Heart

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Congenital Disorders
Interventions
DRUG

Spironolactone (drug)

1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.

Trial Locations (1)

30322

Emory Clinic, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT00211081 - Spironolactone in Patients With Single Ventricle Heart | Biotech Hunter | Biotech Hunter